Patients with previously untreated HER-2 negative operable breast cancer not eligible for neo(adjuvant) treatment were divided into two cohorts, i.e., group A: histologically proven ER+ and/or PgR+ and group B: ER−/PgR− breast cancer (i.e., TNBC). This evidence concerns the gene ERBB2 and breast cancer.